ABSCI CORP Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ABSCI CORP (ABSI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.16 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- ABSCI CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $2.78, a 18.48% decline year-over-year.
- ABSCI CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.41, a 22.15% decline year-over-year.
- ABSCI CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.38, a 113.66% increase year-over-year.
- ABSCI CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.05, a 73.51% decline year-over-year.
- ABSCI CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.16, a 25.12% decline from fiscal 2024.
- ABSCI CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $4.22, a 113.13% increase from fiscal 2023.
- ABSCI CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.98, a 63.33% decline from fiscal 2022.
- ABSCI CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $5.40, a 34.66% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.16 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $2.78 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $3.16 10-K · filed 2026-03-24 | |||
| 2025-09-30 | $3.16 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $3.28 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $3.41 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $4.22 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $4.24 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $4.47 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $4.38 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $1.98 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $2.00 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $2.03 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $2.05 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $5.40 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $6.48 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $7.23 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $7.74 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $4.01 10-K · filed 2022-03-22 | |||
| 2021-09-30 | $3.61 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $2.43 10-Q · filed 2021-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |